Patents by Inventor Barbara A. Sosnowski
Barbara A. Sosnowski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20130190391Abstract: Disclosed are methods for use in transferring nucleic acids into cells at a wound site associated with a fluid space. These gene transfer protocols are suitable for use in transferring various nucleic acids into cartilage, cardiac muscle, and other tissues, and have many uses including treating diseases such as arthritis and ischemic heart disease, and promoting wound healing. The invention further disclosed pharmaceutical compositions that may be used in the practice of the invention to transfer the nucleic acid of interest. Such compositions include any multi-partitioned biocompatible matrix in combination with multiple nucleic acids of interest.Type: ApplicationFiled: August 3, 2012Publication date: July 25, 2013Applicant: CARDIUM BIOLOGICS, INC.Inventors: Barbara A. Sosnowski, Glenn Pierce
-
Publication number: 20100086598Abstract: Disclosed are methods for use in transferring nucleic acids into cells at a wound site associated with a fluid space. These gene transfer protocols are suitable for use in transferring various nucleic acids into cartilage, cardiac muscle, and other tissues, and have many uses including treating diseases such as arthritis and ischemic heart disease, and promoting wound healing. The invention further disclosed pharmaceutical compositions that may be used in the practice of the invention to transfer the nucleic acid of interest. Such compositions include any multi-partitioned biocompatible matrix in combination with multiple nucleic acids of interest.Type: ApplicationFiled: May 11, 2009Publication date: April 8, 2010Applicant: TISSUE REPAIR COMPANYInventors: Barbara A. Sosnowski, Glenn Pierce
-
Patent number: 7534774Abstract: Disclosed are methods for use in transferring nucleic acids into cells at a wound site associated with a fluid space. These gene transfer protocols are suitable for use in transferring various nucleic acids into cartilage, cardiac muscle, and other tissues, and have many uses including treating diseases such as arthritis and ischemic heart disease, and promoting wound healing. The invention further disclosed pharmaceutical compositions that may be used in the practice of the invention to transfer the nucleic acid of interest. Such compositions include any multi-partitioned biocompatible matrix in combination with multiple nucleic acids of interest.Type: GrantFiled: October 2, 2002Date of Patent: May 19, 2009Assignee: Tissue Repair CompanyInventors: Barbara A. Sosnowski, Glenn Pierce
-
Patent number: 7138381Abstract: Preparations of conjugates of a receptor-binding internalized ligand and a cytocide-encoding agent and compositions containing such preparations are provided. The conjugates contain a polypeptide that is reactive with an FGF receptor, such as bFGF, or another heparin-binding growth factor, cytokine, or growth factor coupled to a nucleic acid binding domain. One or more linkers may be used in the conjugation. The linker is selected to increase the specificity, toxicity, solubility, serum stability, or intracellular availability, and promote nucleic acid condensation of the targeted moiety. The conjugates are complexed with a cytocide-encoding agent, such as DNA encoding saporin. Conjugates of a receptor-binding internalized ligand to a nucleic acid molecule are also provided.Type: GrantFiled: July 2, 2002Date of Patent: November 21, 2006Assignee: Prizm Pharmaceuticals, Inc.Inventors: J. Andrew Baird, Lois Ann Chandler, Barbara A. Sosnowski
-
Publication number: 20040029280Abstract: The present invention relates to gene therapy. In particular, therapeutic agents, therapeutic gene products, and compositions are disclosed. Various systems and methods useful in targeting and delivering non-native nucleotide sequences to specific cells are disclosed, wherein virus-antibody-ligand conjugates are used to facilitate targeting and delivery.Type: ApplicationFiled: April 3, 2003Publication date: February 12, 2004Applicants: Selective Genetics, Inc., University of BirminghamInventors: Barbara A. Sosnowski, Andrew Baird, Glenn F. Pierce, David T. Curiel, Joanne T. Douglas, Buck E. Rogers
-
Patent number: 6613563Abstract: The present invention relates to gene therapy. In particular, therapeutic agents, therapeutic gene products, and compositions are disclosed. Various systems and methods useful in targeting and delivering non-native nucleotide sequences to specific cells are disclosed, wherein virus-antibody-ligand conjugates are used to facilitate targeting and delivery.Type: GrantFiled: March 13, 1998Date of Patent: September 2, 2003Assignees: Selective Gentics, Inc., UAB Research FoundationInventors: Barbara A. Sosnowski, Andrew Baird, Glenn F. Pierce, David T. Curiel, Joanne T. Douglas, Buck E. Rogers
-
Publication number: 20030148979Abstract: Disclosed are methods for use in transferring nucleic acids into cells at a wound site associated with a fluid space. These gene transfer protocols are suitable for use in transferring various nucleic acids into cartilage, cardiac muscle, and other tissues, and have many uses including treating diseases such as arthritis and ischemic heart disease, and promoting wound healing. The invention further disclosed pharmaceutical compositions that may be used in the practice of the invention to transfer the nucleic acid of interest. Such compositions include any multi-partitioned biocompatible matrix in combination with multiple nucleic acids of interest.Type: ApplicationFiled: October 2, 2002Publication date: August 7, 2003Applicant: Selective Genetics, Inc.Inventors: Barbara A. Sosnowski, Glenn Pierce
-
Publication number: 20030143217Abstract: Preparations of conjugates of a receptor-binding internalized ligand and a cytocide-encoding agent and compositions containing such preparations are provided. The conjugates contain a polypeptide that is reactive with an FGF receptor, such as bFGF, or another heparin-binding growth factor, cytokine, or growth factor coupled to a nucleic acid binding domain. One or more linkers may be used in the conjugation. The linker is selected to increase the specificity, toxicity, solubility, serum stability, or intracellular availability, and promote nucleic acid condensation of the targeted moiety. The conjugates are complexed with a cytocide-encoding agent, such as DNA encoding saporin. Conjugates of a receptor-binding internalized ligand to a nucleic acid molecule are also provided.Type: ApplicationFiled: July 2, 2002Publication date: July 31, 2003Applicant: Selective Genetics, Inc.Inventors: J. Andrew Baird, Lois Ann Chandler, Barbara A. Sosnowski
-
Publication number: 20030040496Abstract: Methods of treating tumors with preparations of conjugates of a receptor-binding internalized ligand and a cytocide-encoding agent are provided. The conjugates contain a polypeptide that is reactive with an FGF receptor, such as FGF2, or other ligand coupled to a nucleic acid binding domain. One or more linkers may be used in the conjugation. The linker is selected to increase the specificity, toxicity, solubility, serum stability, or intracellular availability, and promote nucleic acid condensation of the targeted moiety. The conjugates are complexed with a cytocide-encoding agent, such as DNA encoding saporin or a prodrug-encoding agent. Conjugates of a receptor-binding internalized ligand to a nucleic acid molecule are also provided.Type: ApplicationFiled: May 17, 2001Publication date: February 27, 2003Inventors: Lois Ann Chandler, Barbara A. Sosnowski, Andrew Baird, Glenn Pierce
-
Patent number: 6503886Abstract: Preparations of conjugates of a receptor-binding internalized ligand and a cytocide-encoding agent and compositions containing such preparations are provided. The conjugates contain a polypeptide that is reactive with an FGF receptor, such as bFGF, or another heparin-binding growth factor, cytokine, or growth factor coupled to a nucleic acid binding domain. One or more linkers may be used in the conjugation. The linker is selected to increase the specificity, toxicity, solubility, serum stability, or intracellular availability, and promote nucleic acid condensation of the targeted moiety. The conjugates are complexed with a cytocide-encoding agent, such as DNA encoding saporin. Conjugates of a receptor-binding internalized ligand to a nucleic acid molecule are also provided.Type: GrantFiled: November 24, 1999Date of Patent: January 7, 2003Assignee: Selective Genetics, Inc.Inventors: J. Andrew Baird, Lois Ann Chandler, Barbara A. Sosnowski
-
Patent number: 6037329Abstract: Preparations of conjugates of a receptor-binding internalized ligand and a cytocide-encoding agent and compositions containing such preparations are provided. The conjugates contain a polypeptide that is reactive with an FGF receptor, such as bFGF, or another heparin-binding growth factor, cytokine, or growth factor coupled to a nucleic acid binding domain. One or more linkers may be used in the conjugation. The linker is selected to increase the specificity, toxicity, solubility, serum stability, or intracellular availability, and promote nucleic acid condensation of the targeted moiety. The conjugates are complexed with a cytocide-encoding agent, such as DNA encoding saporin. Conjugates of a receptor-binding internalized ligand to a nucleic acid molecule are also provided.Type: GrantFiled: September 24, 1996Date of Patent: March 14, 2000Assignee: Selective Genetics, Inc.Inventors: J. Andrew Baird, Lois Ann Chandler, Barbara A. Sosnowski
-
Patent number: 5916772Abstract: Methods for the recombinant production of saporin-containing proteins, including cell surface binding protein-saporin fusion proteins, are provided. The resulting fusion proteins are cytotoxic to targeted cells. In preferred embodiments, methods are provided for the production of basic fibroblast factor (bFGF)-saporin fusion proteins by culturing Escherichia coli that has been transformed with a vector containing DNA encoding bFGF linked via a spacer peptide to the amino terminus of a cytotoxic portion of a saporin polypeptide to obtain expression of the DNA, and isolating the resulting FGF-saporin fusion protein. FGF-saporin fusion proteins and saporin proteins containing from about 5 to 12 amino acid N-terminal extensions are also provided.Type: GrantFiled: April 13, 1995Date of Patent: June 29, 1999Assignee: Whittier Institute for Diabetes and EndocrinologyInventors: Douglas A. Lappi, Isabel Barthelemy, J. Andrew Baird, Barbara A. Sosnowski